Codexis to Report Second Quarter 2024 Financial Results on August 8
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced...
Pharmaceutical
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s...
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader...
Cosmos Health’s Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
CHICAGO, IL / ACCESSWIRE / July 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
eCential Robotics Appoints Clément Vidal as New Chief Executive Officer
GIÈRES (GRENOBLE), France and NASHVILLE, Tenn., July 18, 2024 /PRNewswire/ -- eCential Robotics is pleased to announce the appointment of...
Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor
VANCOUVER, BC, July 18, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased...
Eyenuk Appoints Bryan Haardt as Chief Executive Officer
Haardt brings decades of digital healthcare experience to build on Eyenuk's global mission of using AI to detect and prevent...
K2 Laboratory Obtains NDC Codes for Two Investigational Drugs
K2 Laboratory recently announced that its two investigational drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor oral solution, have successfully...
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer’s biosimilar to Humira®
First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18,...
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation...
Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility
Company poised to execute additional cGMP activities throughout the remainder of the yearDURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) --...
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)VOQUEZNA met its primary endpoint...
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company,...
OPKO Health Announces $100 Million Share Repurchase Program
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has...
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data...
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.MORRISVILLE, N.C.,...
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...